Biosimulation Technology Market Insights, Share and Future Scope

by Vijay K. Web Marketing
The global biosimulation market is growing significantly due to technological advancements and increasing research and development investment in the pharmaceutical and biotechnology industries. Low success rate of drug approval and emerging software applications of biosimulation technology are creating ample opportunities for the global biosimulation technology market to grow at a significant rate in the forecasted period.The advanced research and development facilities and new product developments by the companies are propelling the demand for cost effective biosimulation software.

In biosimulation industry, there is a trend of collaboration and partnership of universities and research institutes with suppliers. Drug discovery and development process is stringent, time consuming, and expensive process. In addition, the success rate of drug approval is very low. According to Tufts Centre for the Study of Drug Development, an academic, non-profit research group at Tufts University, in the U.S., out of 1,000 compounds tested only one makes it to human clinical trials, and out of five such compounds only one gets approved. Biosimulation technology overcomes these limitations by simulating biological systems through software models and increasing predictability in early stages of drug development; hence, saving time and money in drug development process.

Some of the factors driving the growth of the global biosimulation technology market are increasing research and development expenditures, increasing investment in biosimulation training and education programs, technological advancements, increasing focus on reducing drug discovery and development cost, and increasing healthcare expenditure. However, lack of skilled professionals and lack of biosimulation standardization are some of the factors restraining the growth of the global biosimulation technology market to some extent.

Geographically, North America will be leading the global biosimulation technology market in the coming years due to technological advancements, growth in biosimilars and biologics market, high healthcare expenditure, and presence of a large number of pharmaceuticals and biotechnology companies. In addition, the U.S. Food and Drug Administration (FDA), strongly recommends simulation process in drug discovery and development; hence, fueling the growth of biosimulation technology market in North America. Europe is the fastest growing region in the global biosimulation technology market. The major reasons for the fastest growth in the region are high healthcare expenditure and increasing research and development activities.

Some of the major players operating in the global biosimulation technology market Dassault Systemes SA, Simulation Plus Inc., Certara USA, Inc., Advanced Chemistry Development, Inc., In Silico Biosciences, Inc., Chemical Computing Group, Inc., Physiomics PLC., Rhenovia Pharma Ltd., Genedata AG, Entelos Holding Corporation, Leadscope, Inc., and Schrodinger Inc. among others.

Sponsor Ads

About Vijay K. Senior   Web Marketing

211 connections, 3 recommendations, 864 honor points.
Joined APSense since, May 17th, 2016, From New York, United States.

Created on Feb 26th 2019 07:43. Viewed 470 times.


No comment, be the first to comment.
Please sign in before you comment.